Vogenx Inc(VOGX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 4:15 PM ET (Korea 10/1 05:15)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 35.75% | Shs Outstand | 14.9M | Perf Week | -15.15% |
| Market Cap | 0.34B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 9.5M | Perf Month | -32.97% |
| Enterprise Value | 0.34B | PEG | - | EPS next Q | -0.15 | Inst Own | 12.95% | Short Float | 0.27% | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 75.11% | Short Ratio | 0.12 | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 0.03M | Perf YTD | 75.31% |
| Book/sh | -0.12 | P/C | 1781.82 | EPS past 3/5Y | - | ROE | - | 52W High | -40.67% ($38.41) | Perf Year | - |
| Cash/sh | 0.01 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 75.98% ($12.95) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 14.34% 11.72% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 3.66 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.06 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 44.88 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.06 | Sales Q/Q | - | SMA20 | -21.95% ($29.2) | Beta | - | Target Price | $48.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/09/02 | SMA50 | -17.56% ($27.64) | Rel Volume | 0.38 | Prev Close | $24.32 |
| Employees | - | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -17.56% ($27.64) | Avg Volume(3M) | 0.21M | Price | $22.79 |
| IPO | 2026/8/12 | Option/Short | No/Yes | Trades | 1889 | Volume | 79,176 | Change | -6.27% |
Vogenx IncVOGX | NASD | Biotechnology 💊 This is a clinical-stage biotech developing therapies targeting metabolic and gastrointestinal conditions such as post-bariatric surgery hypoglycemia and gastroparesis. Headquartered in the US, it operates with a small team and is concentrating its resources on clinical development of an oral candidate designed to slow intestinal glucose absorption.
Over the past 1 year, roughly in the middle
41% below its 1-year high.
Traded less than usual That is 38% of its average volume.
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 12.9%.
Tap to view numbers
It ranks #262 of 592 in the industry
Based on market cap of $339M.
FAQ
What kind of company is VOGX?
VOGX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VOGX?
The market cap of VOGX is approximately $339M, ranking 3,561 within its sector.
What is the 52-week high and low for VOGX?
VOGX has recorded a 52-week high of $38.41 and a low of $12.95.
